Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

TARRYTOWN, N.Y. and PARIS, Jan. 7, 2019 /PRNewswire/ — Companies select two clinical-stage bispecific antibodies for ongoing collaboration Regeneron retains full rights to all its other investigational immuno-oncology programs; Sanofi able to independently pursue own immuno-oncology…

View more at https://www.prnewswire.com:443/news-releases/regeneron-and-sanofi-restructure-immuno-oncology-collaboration-for-discovery-and-development-programs-300773538.html

No Comments

No comments yet.

Sorry, the comment form is closed at this time.